Trending up symbol


Market size

The market for osteoarthritis treatments is growing rapidly and is expected to be $15.8 billion in 2030. Roughly 80% of this is generated from treatment of knee osteoarthritis.

Unmet needs

There is currently a major demand for osteoarthritis treatments with improved safety and efficacy profiles within the medical community as well as a strong desire to avoid surgery and opioids. The increasing interest in intraarticular combinations offering these benefits is making the SYN321 a great candidate for future treatments.

Our solution

SYN321 has shown beneficial properties with a favorable side effect profile and potential for long-term pain relief in animal studies. The novel therapy of SYN321 could provide patients the ability to live an active life again. A patent has been approved for the unique binding between diclofenac and hyaluronan in SYN321, which offers several competitive advantages including a better side-effect profile compared to competing injectables, opioids, oral diclofenac and other NSAIDs.


There is a clear trend towards injection treatments instead of opioids and NSAIDs due to their side effects. Injections with longer duration are gaining market share. The number of treated osteoarthritis patients are growing with the aging society and an increasingly overweight population.  


The estimated annual revenue potential for SYN321 is estimated at $600M, looking solely at six major markets: The US, France, Germany, Italy, Spain, and the UK. These markets are also Synartro’s primary focus. In addition, the underlying secular growth in demand means even further long-term revenue potential.